LOS ANGELES, April 14, 2023 (GLOBE NEWSWIRE) — The law firm of Portnoy advises Phathom Pharmaceuticals, Inc. FAT Investors that the Company has launched an investigation into possible securities fraud and may be filing a class action lawsuit on behalf of investors. Phathom investors who have lost money investing are encouraged to do so Contact Lesley Portnoy, Esq.

Investors are encouraged to contact an attorney Lesley F Portnoyby phone 844-767-8529 or E-mail: lesley@portnoylaw.comto discuss your legal rights, or Click here to join the case about www.portnoylaw.com. Portnoy Law Firm can provide a free case assessment and discuss investors’ options for making claims to recover their losses.

Phathom Pharmaceuticals issued a press release before the close on August 2, 2022, titled “Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates.” The press release announced that the company found trace amounts of a nitrosamine impurity during post-market approval testing of its vonoprazan drug. Phathom is currently working with the FDA to implement an additional testing procedure, specification, acceptable intake limit and controls to address this issue before commercializing its first Vonoprazan-based products. As a result, the product launches of VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK will be delayed. This news caused Phathom’s share price to fall 28%, or $2.61 per share, to close at $6.46 per share on August 2, 2022.

Please visit our website to verify further information and to submit your transaction information.

Portnoy Law Firm represents investors in asserting claims against companies caused by wrongdoing. The firm’s founding partner has recovered over $5.5 billion for aggrieved investors. attorney advertising. Previous results do not guarantee similar results.

Lesley F. Portnoy, Esq.
Bar Association in CA and NY
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

lawyer advertising